Bone Biologics Corp. (NASDAQ:BBLG) Short Interest Update

Bone Biologics Corp. (NASDAQ:BBLG) was the recipient of a large increase in short interest in May. As of May 29th, there was short interest totaling 4,598 shares, an increase of 58.7% from the May 14th total of 2,897 shares. Based on an average daily volume of 21,087 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.3% of the company’s stock are short sold.

Hedge Funds Weigh In On Bone Biologics

An institutional investor recently raised its position in Bone Biologics stock. DRW Securities LLC boosted its holdings in Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,576 shares of the company’s stock after acquiring an additional 12,549 shares during the quarter. DRW Securities LLC owned 1.31% of Bone Biologics worth $34,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 34.30% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Bone Biologics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, April 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Bone Biologics Stock Down 4.2%

Shares of BBLG opened at $1.38 on Wednesday. The business’s 50 day moving average price is $1.29 and its 200-day moving average price is $1.42. Bone Biologics has a 52 week low of $1.05 and a 52 week high of $6.75. The stock has a market cap of $2.48 million, a P/E ratio of -0.61 and a beta of 0.93.

Bone Biologics (NASDAQ:BBLG) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.43). On average, equities analysts anticipate that Bone Biologics will post -1.52 EPS for the current year.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.